Showing results (301-310 of 392) with videos related to
Sort By:
Pageof 40
European Journal of Haematology|May 2, 2024
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registryNadine Kutsch, Adam Giza, Sandra Robrecht, et al.Blood|June 11, 2015
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy resultsMichael L Wang, Kristie A Blum, Peter Martin, et al.Leukemia & Lymphoma|September 2, 2011
Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemiaClemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, et al.Nature Genetics|January 19, 2016
DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemiaChristopher C Oakes, Marc Seifert, Yassen Assenov, et al.British Journal of Haematology|October 18, 2022
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review studyGeorg Hess, Martin Dreyling, Lucie Oberic, et al.Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.Nature Communications|January 25, 2025
Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLLLavinia Arseni, Gianluca Sigismondo, Haniyeh Yazdanparast, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 26, 2021
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III TrialJohn C Byrd, Peter Hillmen, Paolo Ghia, et al.Hemasphere|May 1, 2026
Chronic lymphocytic leukemia with <i>IGH</i>::<i>BCL3</i>-translocation is characterized by a homogeneous and distinct genetic and epigenetic landscapeCosima Drewes, Cristina López, Juan Emilio Martinez-Manjón, et al.Cell Communication and Signaling : CCS|May 20, 2025
GPR15LG binds CXCR4 and synergistically modulates CXCL12-induced cell signaling and migrationDan Pascal Jean Albers, Sofya Novikova, Julio Vieyto-Nuñez, et al.Pageof 40